Edward E. Kadel

Medicine · Health Sciences

21h-index11.0kcitations94works14.32yr avg
OpenAlex↗ORCID↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Immunotherapy and Biomarkers(64), Bladder and Urothelial Cancer Treatments(43), Urinary and Genital Oncology Studies(31), Prostate Cancer Treatment and Research(24), Radiopharmaceutical Chemistry and Applications(10)

Publications94 total

Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial
Nature Communications·2025· 19 citedOpen Access
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade
Cancer Cell·2024· 28 cited
Real-World Overall Survival and Treatment Patterns by <i>PTEN</i> Status in Metastatic Castration-Resistant Prostate Cancer
JCO Precision Oncology·2024· 7 citedOpen Access
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle Invasive Bladder Cancer
Bladder Cancer·2024· 3 citedOpen Access
Supplementary Fig 1 from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
2023Open Access
Supplementary Tables from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
2023Open Access
Data from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
2023Open Access
Supplementary Tables from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
2023Open Access
Data from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
2023Open Access
Abstract 5456: Application of a multiplex urinalysis test for predicting treatment response in patients with BCG unresponsive bladder cancer: a pilot study
Cancer Research·2023· 2 cited
Supplementary Fig 1 from Tumor Fusion Burden as a Hallmark of Immune Infiltration in Prostate Cancer
2023Open Access
Supplementary Data from Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study
2023Open Access
Supplementary Figure from Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
2023Open Access
Supplementary Figure from Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
2023Open Access
Supplementary Figure from Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
2023Open Access
Supplementary Data from Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
2023Open Access
Supplementary Figure from Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
2023Open Access
Data from Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
2023Open Access
Data from Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
2023Open Access
Supplementary Figure from Clinico-Genomic Characterization of Patients with Metastatic Urothelial Carcinoma in Real-World Practice Identifies a Novel Bladder Immune Performance Index (BIPI)
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Sanjeev Mariathasan(28), Priti S. Hegde(18), Kobe Yuen(17), Thomas Powles(17), Romain Banchereau(13), Hartmut Koeppen(9), Yohann Loriot(9), Marcin Kowanetz(9), Michiel S. van der Heijden(7), Jonathan E. Rosenberg(7), Daniel P. Petrylak(7), Ning Leng(7), Dorothee Nickles(6), Suchit Jhunjhunwala(6), Ira Mellman(6), Shravan Madireddi(6), Patrick Williams(6), Darren Tayama(6), David S. Shames(6), Richard Bourgon(5)